Search academic texts

Information × Registration Number 0218U000389, 0117U001047 , R & D reports Title Defining the role of molecular biomarkers in assessing the aggressiveness of uterine sarcoma popup.stage_title Head Sukhina O.M., Simonova-Pushkar L.I., Registration Date 26-01-2018 Organization State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine" popup.description2 Object of study: combined treatment of uterine sarcomas, molecular and biological characteristics of the tumor. Objective: to increase the efficiency of diagnostics, treatment and prognosis of uterine sarcoma through the determination of the role of some molecular biological characteristics of aggressiveness of uterine sarcoma for the individualization of therapy. Methods and apparatus: roentgenological, morphological, clinical, instrumental, statistical; universal dosimeter UNIDOS-E, ultrasound diagnostic system VOLUSON E8 Expert, OPSYS MR immuno-analyzer photometer. Theoretical and practical results: In this investigation were determined certain differences in indices of matrix metalloproteinases-2, -7, -9 and their tissue inhibitor matrix metalloproteinase-1 in the serum in the group of patients with relapses from the indices of patients undergoing clinical remission. Also were determined expression indices of proliferative activity, markers of apoptosis, suppressor genes and their significance in sarcomas of the uterus. It was found that the MMP-2 rate was significantly lower by 24 % in the group of relapse patients than in patients with remission, and the concentration of MMP-7 in the relapse group was significantly higher by 33.5 % than in the remission group. The index of TIMP-1 in serum of patients with relapses was moderately, but significantly higher than those in patients with remission. Novelty: it was found that the Bcl 2 marker and the presence of progesterone receptor, found in 84.6 and 68.8 % respectively, are positive predictive factors. Moderate to high content of MMP-9 matrix metalloproteinase was revealed in tumor tissue in 80 % of uterine sarcoma, which stipulates for possible development of hematogenous metastases. The effectiveness of implementation: adjuvant CTx is not conducted during six hospitalizations in 60 % of patients with positive progesterone receptors, which saves about 15 thousand UAH for one patient. Field of use: oncology, radiology. Product Description popup.authors Гертман В.З. Грановська Г.І. Долгая О. В. Заднепровська Н.А. Коломацька В.В. Кругова І.М. Лисенко В.Н. Ляховська Н.В. Насонова А.М. Пушкар О. С. Радченко О.А. Сімонова-Пушкар Л.І. Сплюхина О.В. Сухін В.С. Сухіна О.М. Шустов І.Б. Яковенко К.В. popup.nrat_date 2020-04-02 Close